donepezil has been researched along with Amyloid Deposits in 13 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current approved drug treatments for Alzheimer disease (AD) include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and the NMDA receptor antagonist memantine." | 4.88 | New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. ( Caraci, F; Drago, F; Fedotova, J; Leggio, GM; Salomone, S, 2012) |
| "Familial Alzheimer's disease is a very rare autosomal dominant disease with early onset, caused by mutations in the amyloid precursor protein and presenilin genes, both linked to Abeta metabolism." | 2.43 | Alzheimer's disease. ( Blennow, K; de Leon, MJ; Zetterberg, H, 2006) |
| "Also, reduction of amyloid plaque burden and gliosis in the cortex and hippocampus was assessed." | 1.46 | The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease. ( Fernandez, AP; Futch, HS; Herrero-Labrador, R; Marco-Contelles, J; Martínez-Murillo, R; Romero, A; Samadi, A; Serrano, J; Serrano, MP; Unzeta, M, 2017) |
| "Rolipram treatment significantly attenuated STZ induced and age related memory deficits, biochemical and histopathological alterations." | 1.46 | Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type. ( Kumar, A; Singh, N, 2017) |
| " In this study, we sought to determine whether long-term administration of donepezil would slow amyloid plaque deposition or confer neuronal protection in a mouse model of AD." | 1.35 | Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease. ( Coughlan, CA; Csernansky, JG; Dong, H; Murphy, KM; Yuede, CM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Minarini, A | 1 |
| Rosini, M | 1 |
| Tumiatti, V | 1 |
| Recanatini, M | 1 |
| Melchiorre, C | 1 |
| Choi, HJ | 1 |
| Park, JH | 1 |
| Jeong, YJ | 1 |
| Hwang, JW | 1 |
| Lee, S | 1 |
| Lee, H | 1 |
| Seol, E | 1 |
| Kim, IW | 1 |
| Cha, BY | 1 |
| Seo, J | 1 |
| Moon, M | 1 |
| Hoe, HS | 1 |
| Jin, N | 1 |
| Ziyatdinova, S | 1 |
| Gureviciene, I | 1 |
| Tanila, H | 1 |
| Chintamaneni, PK | 1 |
| Krishnamurthy, PT | 1 |
| Rao, PV | 1 |
| Pindiprolu, SS | 1 |
| Yu, D | 1 |
| Tao, BB | 1 |
| Yang, YY | 1 |
| Du, LS | 1 |
| Yang, SS | 1 |
| He, XJ | 1 |
| Zhu, YW | 1 |
| Yan, JK | 1 |
| Yang, Q | 1 |
| Guo, HB | 1 |
| Cheng, YF | 1 |
| Wu, JG | 1 |
| Wang, CM | 1 |
| Wang, HT | 1 |
| Zhang, C | 1 |
| Qiu, ZK | 1 |
| Xu, JP | 1 |
| Serrano, MP | 1 |
| Herrero-Labrador, R | 1 |
| Futch, HS | 1 |
| Serrano, J | 1 |
| Romero, A | 1 |
| Fernandez, AP | 1 |
| Samadi, A | 1 |
| Unzeta, M | 1 |
| Marco-Contelles, J | 1 |
| Martínez-Murillo, R | 1 |
| Kumar, A | 1 |
| Singh, N | 1 |
| Nakamura, Y | 1 |
| Dong, H | 2 |
| Yuede, CM | 1 |
| Coughlan, CA | 1 |
| Murphy, KM | 1 |
| Csernansky, JG | 2 |
| Salomone, S | 1 |
| Caraci, F | 1 |
| Leggio, GM | 1 |
| Fedotova, J | 1 |
| Drago, F | 1 |
| Csernansky, CA | 1 |
| Martin, MV | 1 |
| Bertchume, A | 1 |
| Vallera, D | 1 |
| Blennow, K | 1 |
| de Leon, MJ | 1 |
| Zetterberg, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ageing Gut Brain Interactions[NCT03593941] | 60 participants (Actual) | Observational | 2018-08-02 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for donepezil and Amyloid Deposits
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium | 2008 |
[Diagnosis of and therapy for Alzheimer-type dementia].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antipsychotic Agents; Brain; Cholinesterase Inhibitors; Di | 2008 |
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Topics: Alzheimer Disease; Clinical Trials as Topic; Donepezil; Drug Discovery; Excitatory Amino Acid Antago | 2012 |
Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; | 2006 |
9 other studies available for donepezil and Amyloid Deposits
| Article | Year |
|---|---|
Donepezil ameliorates Aβ pathology but not tau pathology in 5xFAD mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Donepezil; Mice; Mice, Tr | 2022 |
Response of spike-wave discharges in aged APP/PS1 Alzheimer model mice to antiepileptic, metabolic and cholinergic drugs.
Topics: 3-Hydroxybutyric Acid; Action Potentials; Alzheimer Disease; Animals; Anticonvulsants; Atropine; Dis | 2020 |
Surface modified nano-lipid drug conjugates of positive allosteric modulators of M1 muscarinic acetylcholine receptor for the treatment of Alzheimer's disease.
Topics: Acetylcholine; Allosteric Site; Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Cholinestera | 2017 |
The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Berberine; Brain; Cell Survival; Cogniti | 2015 |
Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antigens, CD; Antigens, Differentiat | 2015 |
The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.
Topics: Alzheimer Disease; Animals; Cell Survival; Cerebral Cortex; Disease Models, Animal; Donepezil; Glios | 2017 |
Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type.
Topics: Acetylcholinesterase; Aging; Alzheimer Disease; Animals; Antioxidants; Brain; Cholinesterase Inhibit | 2017 |
Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Biomarkers; Choli | 2009 |
Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Cholinesterase Inhibit | 2005 |